Fenofibrate, which reduces risk of sight-threatening diabetic retinopathy in type 2 diabetes, is associated with early narrowing of retinal venules: a FIELD trial substudy.


Journal

Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952

Informations de publication

Date de publication:
04 2022
Historique:
revised: 04 12 2021
received: 15 09 2021
accepted: 06 12 2021
entrez: 14 4 2022
pubmed: 15 4 2022
medline: 16 4 2022
Statut: ppublish

Résumé

Retinal vessel calibre metrics were evaluated at baseline and 2 years in a FIELD substudy (n = 208). Central retinal venule calibre was significantly reduced by fenofibrate and unchanged by placebo. Arteriole metrics did not change. Larger studies relating retinal vessel calibre to future diabetes complications and response to therapy are merited.

Identifiants

pubmed: 35419960
doi: 10.1111/imj.15733
doi:

Substances chimiques

Fenofibrate U202363UOS

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

676-679

Subventions

Organisme : Laboratoires Fournier
Organisme : National Health and Medical Research Council
Organisme : National Heart Foundation of Australia

Informations de copyright

© 2022 Royal Australasian College of Physicians.

Références

Keech AC, Mitchell P, Summanen P, O'Day J, Davis TM, Moffitt M et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687-97.
ACCORD Study Group, ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363: 233-44.
Nguyen TT, Wang JJ, Sharrett AR, Islam FA, Klein R, Klein BE et al. Relationship of retinal vascular caliber with diabetes and retinopathy: the multi-ethnic study of atherosclerosis (MESA). Diabetes Care 2008; 31: 544-9.
Frydkjaer-Olsen U, Hansen RS, Simó R, Cunha-Vaz J, Peto T, Grauslund J. Correlation between retinal vessel calibre and neurodegeneration in patients with type 2 diabetes mellitus in the European consortium for the early treatment of diabetic retinopathy (EUROCONDOR). Ophthalmic Res 2016; 56: 10-6.
Wong TY, Klein R, Sharrett AR, Schmidt MI, Pankow JS, Couper DJ et al. Retinal arteriolar narrowing and risk of diabetes mellitus in middle-aged persons. JAMA 2002; 287: 2528-33.
Broe R, Rasmussen ML, Frydkjaer-Olsen U, Olsen BS, Mortensen HB, Hodgson L et al. Retinal vessel calibers predict long-term microvascular complications in type 1 diabetes: the Danish cohort of pediatric diabetes 1987 (DCPD1987). Diabetes 2014; 63: 3906-14.
Drobnjak D, Munch IC, Glümer C, Faerch K, Kessel L, Larsen M et al. Relationship between retinal vessel diameters and retinopathy in the Inter99 eye study. J Clin Transl Endocrinol 2017; 8: 22-8.
Scott R, Best J, Forder P, Taskinen M-R, Simes J, Barter P et al. Fenofibrate intervention and event lowering in diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate (ISRCTN64783481). Cardiovasc Diabetol 2005; 4: 13.
Investigators FS. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-61.
Knudtson MD, Lee KE, Hubbard LD, Wong TY, Klein R, Klein BE. Revised formulas for summarizing retinal vessel diameters. Curr Eye Res 2003; 27: 143-9.
Wong TY, Knudtson MD, Klein R, Klein BE, Meuer SM, Hubbard LD. Computer-assisted measurement of retinal vessel diameters in the beaver dam eye study: methodology, correlation between eyes, and effect of refractive errors. Ophthalmology 2004; 111: 1183-90.
Hubbard LD, Brothers RJ, King WN, Clegg LX, Klein R, Cooper LS et al. Methods for evaluation of retinal microvascular abnormalities associated with hypertension/sclerosis in the atherosclerosis risk in communities study. Ophthalmology 1999; 106: 2269-80.
Liew G, Wang JJ, Rochtchina E, Wong TY, Mitchell P. Complete blood count and retinal vessel calibers. PLoS One 2014; 9: e102230.
Cheung N, Rogers SL, Donaghue KC, Jenkins AJ, Tikellis G, Wong TY. Retinal arteriolar dilation predicts retinopathy in adolescents with type 1 diabetes. Diabetes Care 2008; 31: 1842-6.
Yang X, Deng Y, Gu H, Ren X, Lim A, Snellingen T et al. Relationship of retinal vascular calibre and diabetic retinopathy in Chinese patients with type 2 diabetes mellitus: the Desheng diabetic eye study. Br J Ophthalmol 2016; 100: 1359-65.
Klein R, Klein BE, Moss SE, Wong TY. Retinal vessel caliber and microvascular and macrovascular disease in type 2 diabetes: XXI: the Wisconsin epidemiologic study of diabetic retinopathy. Ophthalmology 2007; 114: 1884-92.
Capell WH, DeSouza CA, Poirier P, Bell ML, Stauffer BL, Weil KM et al. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2003; 23: 307-13.
Walker AE, Kaplon RE, Lucking SM, Russell-Nowlan MJ, Eckel RH, Seals DR. Fenofibrate improves vascular endothelial function by reducing oxidative stress while increasing endothelial nitric oxide synthase in healthy normolipidemic older adults. Hypertension 2012; 60: 1517-23.
McGrory S, Taylor AM, Pellegrini E, Ballerini L, Kirin M, Doubal FN et al. Towards standardization of quantitative retinal vascular parameters: comparison of SIVA and VAMPIRE measurements in the Lothian Birth Cohort 1936. Transl Vis Sci Technol 2018; 7: 12.
Yip W, Tham YC, Hsu W, Lee ML, Klein R, Klein B et al. Comparison of common retinal vessel caliber measurement software and a conversion algorithm. Transl Vis Sci Technol 2016; 5: 11.

Auteurs

Nicola Quinn (N)

NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.

Andrzej S Januszewski (AS)

NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.
Department of Medicine (St. Vincent's Hospital), The University of Melbourne, Melbourne, Victoria, Australia.

Laima Brazionis (L)

Department of Medicine (St. Vincent's Hospital), The University of Melbourne, Melbourne, Victoria, Australia.

Rachel O'Connell (R)

NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.

Nanda Aryal (N)

NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.

Justin O'Day (J)

Department of Ophthalmology, The University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.

Russell Scott (R)

Lipid and Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand.

Paul Mitchell (P)

Clinical Ophthalmology and Eye Health, Westmead Clinical School, The University of Sydney, Sydney, New South Wales, Australia.

Alicia J Jenkins (AJ)

NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.
Department of Medicine (St. Vincent's Hospital), The University of Melbourne, Melbourne, Victoria, Australia.

Anthony C Keech (AC)

NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH